| abstract |
Formulations and methods useful to reduce ocular neovascularization (new blood vessels in the cornea, retina, conjunctiva, and/or choroid) are disclosed. According to the invention the formulation will include tetracycline or a derivative thereof including chemically modified tetracyclines (CMT) which inhibit matrix metalloproteinase (MMP) activity at a substantially neutral pH in a pharmaceutically acceptable form suitable for delivery to the eye in an amount and for a duration sufficient to reduce ocular neovascularization. According to the invention the formulations are preferably in pharmaceutically acceptable formulations for topical ocular application, ocular injection, or ocular implantation, and may be contained in liposomes or slow release capsules. |